Sildenafil For Suspension
Product Images NDC 70954-168

17 FDA label images from Ani Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 70954-168). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of sildenafil citrate, the active ingredient in Sildenafil oral suspension 10 mg/mL by ANI Pharmaceuticals, Inc. The diagram shows the molecular arrangement of atoms and bonds specific to sildenafil citrate.*
FDA Label Image

Figure7 (Figure7)

Figure7 (Figure7)
A forest plot depicting drug interaction effects on Sildenafil pharmacokinetics, showing fold change and 90% confidence intervals for AUC and Cmax of various interacting drugs relative to Sildenafil alone. Recommendations for dose adjustment accompany each interaction, with most advising no dose adjustment except for Ritonavir, which is not recommended for coadministration.*
FDA Label Image

Figure8 (Figure8)

Figure8 (Figure8)
A chart showing fold change and 90% confidence intervals for sildenafil pharmacokinetics or pharmacodynamics when coadministered with various interacting drugs. The x-axis depicts change relative to the interacting drug alone. The chart includes drugs like Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin, Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide, with recommendations for dose adjustment or coadministration noted.*
FDA Label Image

Figure-3 (Figure 9)

Figure-3 (Figure 9)
A line graph showing change from baseline in meters over study weeks 4, 8, and 12 for different Sildenafil dosages (40 mg TID, 20 mg TID, 80 mg TID) and placebo. The vertical axis represents change from baseline in meters, the horizontal axis shows weeks of study, and error bars indicate variability for each data point.*
FDA Label Image

Figure-4 (Figure 10)

Figure-4 (Figure 10)
A forest plot chart showing placebo-corrected change in 6-minute walk distance (in meters) for Sildenafil 20 mg TID across various baseline characteristics such as baseline walk distance, etiology, functional capacity class, gender, age, mean PAP, and PVRI. The plot includes patient counts for placebo and Sildenafil groups and error bars indicating variability in each subgroup.*
FDA Label Image

Figure-5 (Figure 11)

Figure-5 (Figure 11)
A line graph comparing the percentage of subjects without a clinically worsening event over time between placebo and sildenafil groups. The x-axis represents days from randomization (0 to 112 days), and the y-axis shows the percentage without worsening events. Sildenafil group shows a higher percentage consistently than placebo over the study period.*
FDA Label Image

Ifu-1 (Ifu 1)

Ifu-1 (Ifu 1)
Illustration showing components of Sildenafil oral suspension 10 mg/mL packaging and dosing syringe. The suspension bottle includes a cap, bottle adaptor, and label with a discard after date. The oral dosing syringe is labeled with tip, barrel, and plunger parts for measuring doses.*
FDA Label Image

Ifu-2 (Ifu 2)

Ifu-2 (Ifu 2)
An instructional illustration showing a hand holding a bottle, indicating movement directions for shaking or mixing the liquid inside by rotating and shaking up and down. Next to the bottle is a stopwatch representing a 10-second time interval, suggesting the time needed for this action.*
FDA Label Image

Ifu-3 (Ifu 3)

Ifu-3 (Ifu 3)
An instructional illustration demonstrating how to properly close the cap of a medication bottle for suspension. It shows a hand pressing down on the cap while turning it in a clockwise direction to secure it.*
FDA Label Image

Ifu-4 (Ifu 4)

Ifu-4 (Ifu 4)
An instructional illustration showing how to withdraw medication from a suspension bottle using a syringe. The left inset shows pressing down on the syringe plunger to expel air, while the main image depicts inserting the syringe into the bottle and drawing liquid upward by pulling the plunger. This demonstrates proper technique for preparing an oral suspension dose.*
FDA Label Image

Ifu-5 (Ifu 5)

Ifu-5 (Ifu 5)
An instructional illustration showing a hand holding an inverted bottle above a graduated oral syringe. The syringe is positioned below the bottle's opening to draw liquid medication, demonstrating how to measure and withdraw a dose for oral suspension.*
FDA Label Image

Ifu-6 (Ifu 6)

Ifu-6 (Ifu 6)
An instructional illustration showing a hand holding a bottle while another hand pulls a syringe upward from the bottle's opening. The figure is labeled as Figure F, indicating a step in medication preparation or administration for an oral suspension.*
FDA Label Image

Ifu-7 (Ifu 7)

Ifu-7 (Ifu 7)
An instructional line drawing showing the administration of oral suspension using a syringe for an adult. The illustration depicts a hand holding a dosing syringe directed into the mouth, indicating how to properly dispense medication orally.*
FDA Label Image

Ifu-8 (Ifu 8)

Ifu-8 (Ifu 8)
An instructional illustration showing a hand gripping the cap of a bottle, with arrows indicating the twisting motion to open or close the bottle. The bottle is filled to near the top. This figure is labeled as 'Figure H'.*
FDA Label Image

Ifu-9 (Ifu 9)

Ifu-9 (Ifu 9)
An instructional diagram labeled Figure 1 showing two oral syringes being filled under a running faucet. The image likely demonstrates how to fill the syringes with liquid medication for oral suspension dosing.*
FDA Label Image

Newcarton (Newcarton)

Newcarton (Newcarton)
This is the packaging label for Sildenafil for Oral Suspension, 10 mg/mL, by Novitium Pharma. It is a 112 mL grape-flavored oral suspension for prescription use only. The label includes storage and reconstitution instructions, dosage information, and manufacturer details from Novitium Pharma LLC in East Windsor, New Jersey.*
FDA Label Image

Newcontainer (Newcontainer)

Newcontainer (Newcontainer)
Label for Sildenafil for Oral Suspension 10 mg/mL, a prescription oral suspension. The label includes storage instructions before and after reconstitution, dosage information stating each mL contains 10 mg of sildenafil citrate when reconstituted with 90 mL water, and a total bottle content of 112 mL. It specifies the product is grape flavored, manufactured by Novitium Pharma LLC, East Windsor, New Jersey. It also includes a barcode and notes to shake well before use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.